Merck KGaA (FRA:MRK) received a €93.00 ($108.14) price target from investment analysts at Credit Suisse Group in a research note issued on Tuesday, October 23rd. The firm currently has a “neutral” rating on the healthcare company’s stock. Credit Suisse Group’s target price suggests a potential downside of 4.75% from the company’s current price.
A number of other research firms have also commented on MRK. Kepler Capital Markets set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Friday, October 19th. Commerzbank set a €100.00 ($116.28) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, October 17th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Merck KGaA in a research report on Wednesday, October 17th. UBS Group set a €115.00 ($133.72) target price on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, October 17th. Finally, Goldman Sachs Group set a €92.00 ($106.98) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of €98.00 ($113.95).
Shares of MRK traded up €4.14 ($4.81) during trading hours on Tuesday, reaching €97.64 ($113.53). 779,281 shares of the company traded hands. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: How can you know how many shares are floating?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.